In last trading session, Tourmaline Bio Inc (NASDAQ:TRML) saw 0.63 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $18.80 trading at $1.76 or 10.33% at ring of the bell on the day assigns it a market valuation of $482.08M. That closing price of TRML’s stock is at a discount of -146.6% from its 52-week high price of $46.36 and is indicating a premium of 36.86% from its 52-week low price of $11.87. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.31 million shares which gives us an average trading volume of 271.09K if we extend that period to 3-months.
Tourmaline Bio Inc (NASDAQ:TRML) trade information
Upright in the green during last session for gaining 10.33%, in the last five days TRML remained trading in the green while hitting it’s week-highest on Friday, 03/14/25 when the stock touched $18.80 price level, adding 0.11% to its value on the day. Tourmaline Bio Inc’s shares saw a change of -7.30% in year-to-date performance and have moved 30.74% in past 5-day. Tourmaline Bio Inc (NASDAQ:TRML) showed a performance of 42.10% in past 30-days. Number of shares sold short was 3.42 million shares which calculate 10.57 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 46 to the stock, which implies a rise of 59.13% to its current value. Analysts have been projecting 42 as a low price target for the stock while placing it at a high target of 50. It follows that stock’s current price would drop -123.4% in reaching the projected high whereas dropping to the targeted low would mean a loss of -123.4% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.04% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -21.68% while estimates for its earnings growth in next 5 years are of -19.64%.
Tourmaline Bio Inc (NASDAQ:TRML)’s Major holders
Insiders are in possession of 22.58% of company’s total shares while institution are holding 85.74 percent of that, with stock having share float percentage of 110.75%. Investors also watch the number of corporate investors in a company very closely, which is 85.74% institutions for Tourmaline Bio Inc that are currently holding shares of the company. RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at TRML for having 2.54 million shares of worth $32.65 million. And as of 2024-06-30, it was holding 9.8699 of the company’s outstanding shares.
The second largest institutional holder is AVORO CAPITAL ADVISORS LLC, which was holding about 2.22 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.6387 of outstanding shares, having a total worth of $28.58 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 647.38 shares of worth $12.17 million or 2.52% of the total outstanding shares. The later fund manager was in possession of 620.32 shares on Dec 31, 2024 , making its stake of worth around $11.66 million in the company or a holder of 2.42% of company’s stock.
